A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
A Phase II Study of JS212 Monotherapy or Combination Therapy With JS207 or JS001 in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
The study consists of 2 parts. Both parts consist of safety run-in period and cohort expansion period. Safety run-in period will enroll those who have received only 1 line of prior systemic standard treatment. Cohort expansion period will enroll those are treated naive or recived treatment in adjuvant phase.
Part 1 will receive JS212 monotherapy or combination therapy with JS207, based on the PD-L1 expression. Part 2 will receive JS212 in combination with JS001.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Chaoqiang Yang, PM
- Telefonnummer: 18252095266
- E-post: chaoqiang_yang@junshipharma.com
Studiesteder
-
-
-
Beijing, Kina
- Rekruttering
- Peking University People's Hospital
-
Ta kontakt med:
- Shu Wang, PhD.
- Telefonnummer: 13801080201
- E-post: dr.wangshu@263.net
-
Hovedetterforsker:
- Shu Wang, Ph.D.
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100144
- Har ikke rekruttert ennå
- Peking University Shougang Hospital
-
Ta kontakt med:
- Xueli Mo, Master
- Telefonnummer: 13699180225
- E-post: xuelimo@hotmail.com
-
Hovedetterforsker:
- Xueli Mo, Master
-
Beijing, Beijing Municipality, Kina, 100071
- Har ikke rekruttert ennå
- The Fifth Medical Center of Chinese PLA General Hospital
-
Ta kontakt med:
- Shaohua Zhang, Doctor
- Telefonnummer: 13311591557
- E-post: zhangsh19760428@163.com
-
Hovedetterforsker:
- Shaohua Zhang, Doctor
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350000
- Har ikke rekruttert ennå
- Fujian Cancer Hospital
-
Ta kontakt med:
- Fan Wu, Ph.D.
- Telefonnummer: 13859082118
- E-post: wufan_fj@163.com
-
Hovedetterforsker:
- Fan Wu, Ph.D.
-
-
Gansu
-
Lanzhou, Gansu, Kina, 730000
- Har ikke rekruttert ennå
- The First Hospital of Lanzhou University
-
Ta kontakt med:
- Xiaoling Ling, Ph.D.
- Telefonnummer: 18693165668
- E-post: lingxiaolingedu@163.com
-
Hovedetterforsker:
- Xiaoling Ling, Ph.D.
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Har ikke rekruttert ennå
- Sun Yat-sen University Cancer Center
-
Ta kontakt med:
- Shusen Wang, Ph.D.
- Telefonnummer: 13926168469
- E-post: wangshs2019@163.com
-
Hovedetterforsker:
- Shusen Wang, Ph.D.
-
Guangzhou, Guangdong, Kina, 510080
- Har ikke rekruttert ennå
- Guangdong General Hospital
-
Ta kontakt med:
- Kun Wang, Ph.D.
- Telefonnummer: 13922118086
- E-post: bzwangkun@163.com
-
Hovedetterforsker:
- Kun Wang, Ph.D.
-
-
Guizhou
-
Guiyang, Guizhou, Kina, 550004
- Har ikke rekruttert ennå
- The Affiliated Hospital of Guizhou Medical University
-
Ta kontakt med:
- Shu Liu, Ph.D.
- Telefonnummer: 13908516963
- E-post: drliushu@163.com
-
Hovedetterforsker:
- Shu Liu, Ph.D.
-
Guiyang, Guizhou, Kina, 550001
- Har ikke rekruttert ennå
- The Affiliated Cancer Hospital of Guizhou Medical University City: Guiyang
-
Ta kontakt med:
- Zhihong Wang, Bachelor
- Telefonnummer: 13595159308
- E-post: Wzh1968626@sina.com
-
Hovedetterforsker:
- Zhihong Wang, Bachelor
-
-
Hebei
-
Baoding, Hebei, Kina, 071000
- Har ikke rekruttert ennå
- Affiliated Hospital of Hebei University
-
Ta kontakt med:
- Hua Yang, Ph.D.
- Telefonnummer: 18603120729
- E-post: docyh@163.com
-
Hovedetterforsker:
- Hua Yang, Ph.D.
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Har ikke rekruttert ennå
- Harbin Medical University Cancer Hospital
-
Ta kontakt med:
- Wenhui Zhao, Ph.D.
- Telefonnummer: 18745177632
- E-post: zhaowenhui1977@163.com
-
Hovedetterforsker:
- Wenhui Zhao, Ph.D.
-
-
Henan
-
Zhengzhou, Henan, Kina, 450001
- Har ikke rekruttert ennå
- The First Affiliated Hospital of Zhengzhou University
-
Ta kontakt med:
- Hong Zong, Ph.D.
- Telefonnummer: 13623586882
- E-post: zonghong522@126.com
-
Hovedetterforsker:
- Hong Zong, Ph.D.
-
Zhengzhou, Henan, Kina, 450002
- Har ikke rekruttert ennå
- Henan Cancer Hospital
-
Ta kontakt med:
- Min Yan, Ph.D.
- Telefonnummer: 15713857388
- E-post: ym200678@126.com
-
Hovedetterforsker:
- Min Yan, Ph.D.
-
-
Hubei
-
Wuhan, Hubei, Kina, 430079
- Har ikke rekruttert ennå
- Hubei Cancer Hospital
-
Ta kontakt med:
- Xinhong Wu, Ph.D.
- Telefonnummer: 18602726300
- E-post: Xinhongwuhbch@163.com
-
Hovedetterforsker:
- Xinhong Wu, Ph.D.
-
-
Hunan
-
Changde, Hunan, Kina, 415003
- Har ikke rekruttert ennå
- The First People's Hospital of Changde City
-
Ta kontakt med:
- Hui Li, Ph.D.
- Telefonnummer: 15886648808
- E-post: 373099626@qq.com
-
Hovedetterforsker:
- Hui Li, Ph.D.
-
Changsha, Hunan, Kina, 410013
- Har ikke rekruttert ennå
- Hunan Cancer Hospital
-
Ta kontakt med:
- Quchang Ouyang, Ph.D.
- Telefonnummer: 13973135318
- E-post: oyqc1969@126.com
-
Hovedetterforsker:
- Quchang Ouyang, Ph.D.
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210029
- Har ikke rekruttert ennå
- Jiangsu Province Hospital
-
Ta kontakt med:
- Wei Li, Ph.D.
- Telefonnummer: 13851603656
- E-post: real.lw@163.com
-
Hovedetterforsker:
- Wei Li, Ph.D.
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330009
- Har ikke rekruttert ennå
- Nanchang People's Hospital
-
Ta kontakt med:
- Wenyan Chen, Bachelor
- Telefonnummer: 18679168977
- E-post: chenwenyannc2013@163.com
-
Hovedetterforsker:
- Wenyan Chen, Bachelor
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Har ikke rekruttert ennå
- The First Hospital of Jilin University
-
Ta kontakt med:
- Lihua Kang, Ph.D.
- Telefonnummer: 13504334518
- E-post: kanglihua961002@163.com
-
Hovedetterforsker:
- Lihua Kang, Ph.D.
-
Changchun, Jilin, Kina, 130012
- Har ikke rekruttert ennå
- Jilin Provincial Cancer Hospital
-
Ta kontakt med:
- Fei Chen, Master
- Telefonnummer: 18604430968
- E-post: Email:flyrcf@163.com
-
Hovedetterforsker:
- Fei Chen, Master
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110022
- Har ikke rekruttert ennå
- Shengjing Hospital of China Medical University
-
Ta kontakt med:
- Xihe Zhao, Ph.D.
- Telefonnummer: 18940259508
- E-post: zhaoxh@sj-hospital.org
-
Hovedetterforsker:
- Xihe Zhao, Ph.D.
-
Shenyang, Liaoning, Kina, 110042
- Har ikke rekruttert ennå
- Cancer Hospital of Dalian University of Technology(Liaoning Cancer Hospital & Institute)
-
Ta kontakt med:
- Tao Sun, Ph.D.
- Telefonnummer: 13940404526
- E-post: lnzlrxnsy@163.com
-
Hovedetterforsker:
- Tao Sun, Ph.D.
-
Shenyang, Liaoning, Kina, 110167
- Har ikke rekruttert ennå
- Introduction to the First Affiliated Hospital of China Medical University
-
Ta kontakt med:
- Yuee Teng, Ph.D.
- Telefonnummer: 13591639797
- E-post: tengyuee517@yahoo.com.cn
-
Hovedetterforsker:
- Yuee Teng, Ph.D.
-
-
Ningxia
-
Yinchuan, Ningxia, Kina, 750000
- Har ikke rekruttert ennå
- General Hospital of Ningxia Medical University
-
Ta kontakt med:
- Ye Lv, Bachelor
- Telefonnummer: 18709515757
- E-post: liuweilvye@yeah.net
-
Hovedetterforsker:
- Ye Lv, Bachelor
-
-
Shandong
-
Jinan, Shandong, Kina, 250117
- Har ikke rekruttert ennå
- Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
-
Ta kontakt med:
- Qi Dang, Master
- Telefonnummer: 15318816098
- E-post: dangqi123456@126.com
-
Ta kontakt med:
- Huihui Li, Ph.D.
- Telefonnummer: 15553103209
- E-post: 15553103209@163.com
-
Hovedetterforsker:
- Huihui Li, Ph.D.
-
Jining, Shandong, Kina, 272000
- Har ikke rekruttert ennå
- Affiliated Hospital of Jining Medical University
-
Ta kontakt med:
- Changping Shan, Master
- Telefonnummer: 18678766865
- E-post: scp9933@163.com
-
Hovedetterforsker:
- Changping Shan, Master
-
Qingdao, Shandong, Kina, 266000
- Har ikke rekruttert ennå
- The Affiliated Hospital of Qingdao University
-
Ta kontakt med:
- Haibo Wang, Ph.D.
- Telefonnummer: 18661805787
- E-post: hbwangqy@126.com
-
Hovedetterforsker:
- Haibo Wang, Ph.D.
-
Weifang, Shandong, Kina, 261000
- Har ikke rekruttert ennå
- Weifang People's Hospital
-
Ta kontakt med:
- Wenhui Wang, Ph.D.
- Telefonnummer: 18605368857
- E-post: wwh8857@163.com
-
Hovedetterforsker:
- Wenhui Wang, Ph.D.
-
-
Shanxi
-
Taiyuan, Shanxi, Kina, 030013
- Har ikke rekruttert ennå
- Shanxi Cancer Hospital
-
Ta kontakt med:
- Guohui Han, Ph.D.
- Telefonnummer: 13754858188
- E-post: 13754858188@163.com
-
Hovedetterforsker:
- Guohui Han, Ph.D.
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610072
- Har ikke rekruttert ennå
- Sichuan Provincial People's Hospital
-
Ta kontakt med:
- Jing Luo, Ph.D.
- Telefonnummer: 18981838521
- E-post: jingluopi@163.com
-
Hovedetterforsker:
- Jing Luo, Ph.D.
-
Mianyang, Sichuan, Kina
- Har ikke rekruttert ennå
- Mianyang Central Hospital
-
Ta kontakt med:
- Zhen zhang, Master
- Telefonnummer: 13778159530
- E-post: jiangzhangtong@sina.com
-
Hovedetterforsker:
- Zhen Zhang, Master
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female age 18-70 years old;
- Voluntary participation in clinical study;
- Histologically confirmed unresectable, locally advanced or metastatic triple-negative breast cancer(absence of HER2, ER, and PR expression);
- No prior systemic antitumor therapy for locally advanced or Metastatic TNBC(cohort expansion period); only one line of prior systemetic treatment for locally advanced or metastatic TNBC;
- Adequate organ function;
- ECOG performance status of 0 or 1;
- Life expectancy 12 weeks;
- Measurable disease, as defined by RECIST v1.1;
Exclusion Criteria:
- Untreated or active central nervous system (CNS) metastases;
- Uncontrolled pleural effusion, pericardial effusion or ascites;
- Tumor encasement of important vessels or significant necrosis and cavitation that may cause a risk of hemorrhage;
- History of significant bleeding tendency or severe coagulation disorder;
- Uncontrolled hypertension;
- Active autoimmune diseases requiring systemic treatmen within 2 years prior to the first dose;
- History of interstitial lung disease or previous Noninfectious pneumonitis treated with corticosteroids, or evidence of active Pneumonia in radiology on screening period;
- History of immunodeficiency. Presence of active tuberculosis, hepatitis B, or hepatitis C;
- Severe cardiovascular disease;
- Serious infection (CTCAE 6.0 Grade>2) within 28 days prior to the first dose of study drug;
- Previous treatment of any anti-VRGF drugs targeting VEGF (part 1) or ADC drugs targeting EGFR and/or HER3;
- History of another malignancy within 5 years before the first dose of study drug;
- Not suitable to receive study treatment for other conditions as per investigator;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort A
JS212 in combination with JS207,CPS≥10 |
JS212 and JS207 will be administered intravenously on D1, Q3W |
|
Eksperimentell: Cohort B
JS212 monotherapy, CPS<10 |
JS212 will be administered intravenously on D1,Q3W |
|
Eksperimentell: Cohort C
JS212 in combination with JS207, CPS<10 |
JS212 and JS207 will be administered intravenously on D1, Q3W |
|
Eksperimentell: Cohort D
JS212 in combination with JS001 |
JS212 and JS001 will be administered intravenously on D1, Q3W |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate(ORR)
Tidsramme: 24 months
|
Objective response rate(ORR) evaluated based on RECIST v1.1 |
24 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of response (DoR)
Tidsramme: 24 months
|
Duration of response (DoR) evaluated based on RECIST v1.1 |
24 months
|
|
Disease control rate (DOR)
Tidsramme: 24 months
|
Disease control rate (DOR)evaluated based on RECIST v1.1 |
24 months
|
|
Progression free survival (PFS)
Tidsramme: 24 months
|
Progression free survival (PFS) evaluated based on RECIST v1.1 |
24 months
|
|
Overall Survival (OS)
Tidsramme: 36 months
|
Overall Survival (OS)evaluated based on RECIST v1.1 |
36 months
|
|
Adverse Events
Tidsramme: 24 months
|
Incidence and severity of Adverse Events(AEs)according to NCI-CTCAE v6.0 |
24 months
|
|
Immunogenicity
Tidsramme: 24 months
|
The incidence of Nab(if applicable) of JS212 and JS207 |
24 months
|
|
Plasma concentrations
Tidsramme: 2 years
|
Plasma concentrations of JS207 and 9MW2821 |
2 years
|
|
PD-L1 expression
Tidsramme: 2 years
|
The correlation between PD-L1 expression in tumor tissue and therapeutic efficacy |
2 years
|
|
EGFR/HER expression
Tidsramme: 2 years
|
The correlation between EGFR/HER3 expression in tumor tissue and therapeutic efficacy |
2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- JS212-009-II-BC
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .